CDC

Research!America’€™s National Health Research Forum ’€” held September 12 at the Newseum’€™s Knight Conference Center in Washington, DC ’€” examined the current and future state of research to improve health. This year’€™s theme was ’€œStraight Talk about the Future of Medical and Health Research.’€ Three expert panels delved into different aspects of the research ecosystem. Research!America’€™s president and CEO, Mary Woolley, and chair, The Honorable John Edward Porter, opened the program. Porter introduced Bart Peterson, JD, senior vice president of corporate affairs and communications at Lilly who delivered a brief keynote speech. ’€œWe developed an innovation ecosystem, and that...
Research!America’€™s National Health Research Forum ’€” held September 12 at the Newseum’€™s Knight Conference Center in Washington, DC ’€” examined the current and future state of research to improve health. This year’€™s theme was ’€œStraight Talk about the Future of Medical and Health Research.’€ Three expert panels delved into different aspects of the research ecosystem. Research!America’€™s president and CEO, Mary Woolley, and chair, The Honorable John Edward Porter, opened the program. Porter introduced Bart Peterson, JD, senior vice president of corporate affairs and communications at Lilly who delivered a brief keynote speech. ’€œWe developed an innovation ecosystem, and that...
Dear Research Advocate: Although Congress officially returns next week, many Members are back in Washington as the debate about the crisis in Syria commands center stage. Members also face looming fiscal deadlines, with only nine legislative days scheduled in September to act on those and a large backlog of other legislation. Given all this, it is not hard to predict how Congress will handle the long- or short-term budget resolutions, debt ceiling, the future of sequestration, tax and entitlement reform, and a myriad of other interconnected items: They will put off decision-making. Thus a continuing resolution (“CR”), extending FY13 budgets, looks likely, once again kicking the can down the...
We Need to Make that Happen Congress will be making funding decisions for all or part of FY14 in September, and it may also decide whether to eliminate, modify or simply leave in place the annual, arbitrary budget cuts known as sequestration. If we want the federal government to continue to adequately seed the research pipeline so that researchers can find treatments and cures for deadly diseases like cancer and Alzheimer’€™s, Congress needs to hear from us. Now. Tell your representatives in Congress to speak out and fight for the National Institutes of Health, the Centers for Disease Control and Prevention, and the other health agencies that spur medical progress and safeguard the health...
Dear Research Advocate: Although Congress officially returns next week, many Members are back in Washington as the debate about the crisis in Syria commands center stage. Members also face looming fiscal deadlines, with only nine legislative days scheduled in September to act on those and a large backlog of other legislation. Given all this, it is not hard to predict how Congress will handle the long- or short-term budget resolutions, debt ceiling, the future of sequestration, tax and entitlement reform, and a myriad of other interconnected items: They will put off decision-making. Thus a continuing resolution (“CR”), extending FY13 budgets, looks likely, once again kicking the can down the...
We Need to Make that Happen Congress will be making funding decisions for all or part of FY14 in September, and it may also decide whether to eliminate, modify or simply leave in place the annual, arbitrary budget cuts known as sequestration. If we want the federal government to continue to adequately seed the research pipeline so that researchers can find treatments and cures for deadly diseases like cancer and Alzheimer’€™s, Congress needs to hear from us. Now. Tell your representatives in Congress to speak out and fight for the National Institutes of Health, the Centers for Disease Control and Prevention, and the other health agencies that spur medical progress and safeguard the health...
Op-ed by The Honorable John Edward Porter, Research!America Chair and former U.S. Representative (1980 ’€“ 2001) published in CNN . At every congressional recess, the question remains: What has Congress accomplished to advance medical innovation, or for that matter any of our national priorities? A ritual of leaving town with no meaningful action on pressing issues seems to have taken hold as lawmakers once again meet with voters in their districts. Indeed, much will happen during this break, but as elected officials hold yet another town hall meeting, Facebook or Twitter chat or public event, thousands will be diagnosed with cancer or get the dreaded confirmation from a physician that they...
Op-ed by The Honorable John Edward Porter, Research!America Chair and former U.S. Representative (1980 ’€“ 2001) published in CNN . At every congressional recess, the question remains: What has Congress accomplished to advance medical innovation, or for that matter any of our national priorities? A ritual of leaving town with no meaningful action on pressing issues seems to have taken hold as lawmakers once again meet with voters in their districts. Indeed, much will happen during this break, but as elected officials hold yet another town hall meeting, Facebook or Twitter chat or public event, thousands will be diagnosed with cancer or get the dreaded confirmation from a physician that they...
Dear Research Advocate: The Bureau of Economic Analysis has reclassified research and development costs from an “expense” to an “investment” when calculating GDP. We think Members of Congress should do the same. Common sense tells us R&D is an investment, not an expense; in general conversation we all talk about R&D as an investment, but it isn’€™t accounted for that way on the federal books. The arguments we’€™ve been making are now further bolstered by the BEA’€™s decision. Spread the word! One hundred and sixty five university presidents and chancellors, representing all 50 states, have called on the president and Congress to reverse the pending “innovation deficit” in an open...
Dear Research Advocate: The Bureau of Economic Analysis has reclassified research and development costs from an “expense” to an “investment” when calculating GDP. We think Members of Congress should do the same. Common sense tells us R&D is an investment, not an expense; in general conversation we all talk about R&D as an investment, but it isn’€™t accounted for that way on the federal books. The arguments we’€™ve been making are now further bolstered by the BEA’€™s decision. Spread the word! One hundred and sixty five university presidents and chancellors, representing all 50 states, have called on the president and Congress to reverse the pending “innovation deficit” in an open...

Pages

Sidebar Quote

Without continued support for health research, many of the most promising young scientists, their ideas and a myriad of potentially life-changing scientific breakthroughs will vanish into oblivion.
Paul Marinec, PhD; University of California San Francisco